Invokana Lawsuit And Recent FDA Side Effect Warnings Cause Concern Over SGLT2 Inhibitor Drugs

February 26, 2016 – – TheProductLawyers.com reports on new Invokana news, which shows that the drug has been linked to over 50 reports of kidney failure and renal impairment in those who have taken it. Invokana is a new-generation, type-2 diabetes drug, which many consumers now feel poses a severe kidney risk that users should be aware of and certain that they understand.

Invokana was approved by the U.S. Food and Drug Administration in 2013, and was then released to market. It was approved to treat patients struggling with type-2 diabetes. The drug works by controlling blood sugar (glucose) levels in these patients by helping them to dispose of any excess sugar in their bodies through their urine. Invokana was the first of several similar drugs released called SGLT2 class inhibitors.

The U.S. Food and Drug Administration (FDA) recently issued a safety warning discussing required changes which manufacturer Janssen Pharmaceuticals must make to the warning label on Invokana. This was announced on December 4th of 2015. The FDA has noted that, because of recent adverse event reports concerning Invokana and SGLT2 inhibitors; most notably reports of patients developing life-threatening conditions, it was necessary to adjust the drug’s warning label. Although the FDA had also received reports that Invokana patients required hospitalization and treatment for kidney failure, the warning label adjustments will focus on better emphasizing the drug’s potential link to ketoacidosis and urinary tract infections at this time.

In addition to the FDA’s latest product label request regarding the drug, Invokana was the topic of a May 2015 warning issued by the Institute for Safe Medication Practices. The agency published this warning in their QuarterWatch report, stating that Invokana had been linked to over 450 adverse event reports in only one year. Over 50 of these adverse event reports highlighted renal impairment or kidney failure among patients.

Sadly, after sustaining kidney damage, patients are unable to heal or reverse it. The only option in these circumstances is a complete kidney transplant, which can be very difficult to obtain. While waiting and hoping for donor kidney transplants, these patients usually require dialysis treatments.

The attorneys of Banville Law sponsor the online resource website TheProductLawyers.com, dedicated to informing the public of the latest important news on Invokana and other drugs. They are also currently helping anyone who has been negatively affected after taking Invokana or another SGLT2 inhibitor drug to evaluate their legal rights in full. These patients may be entitled to legal action and substantial compensation. In an effort help those deserving of justice, Banville Law is offering free legal consultations for qualified individuals at this time.

To request additional information on Invokana, or to ask questions, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008386